Insights

Scientific commentary, market intelligence, and field-tested founder guidance.

Written by the Quadros Bio scientific team. Articles publish here on a rolling basis.

Read the latest briefings →

Can Brazilian biological inputs really work in North American soils?

Editorial pipeline

Four categories. Short evidence-backed pieces.

Scope

Four categories.

Biologicals Risk Notes

Short essays on where biological products fail and what investors and founders can learn from those failure patterns. Strain identity, mode-of-action claims, formulation stability, field translation probability, and the gap between lab signal and commercial behavior.

Planned pieces include

·Why lab performance does not guarantee field performance
·How investors should assess microbial strain identity
·The hidden risk in biological formulation stability
·Why mode-of-action claims matter

Brazil Market Intelligence

Short market notes on the Brazilian agricultural biologicals landscape. Regulatory pathways at MAPA and SISGEN, comparison with North American CFIA and EPA frameworks, Embrapa and federal university innovation pipelines, and the cross-border opportunities most North American investors do not see in time.

Planned pieces include

·Why Brazil matters in agricultural biologicals
·How Brazilian field trial culture differs from North America
·What North American investors misunderstand about Brazilian AgBio
·Regulatory translation: MAPA, EPA, PMRA, CFIA

QBIView Case Notes

Anonymized or fictionalized case studies illustrating what the QBIView framework surfaces in assessments. The patterns that recur. The red flags that get missed. The deals that should have closed differently.

Planned pieces include

·A nitrogen-fixing inoculant with strong lab data but weak field translation
·A biostimulant with unclear regulatory claims
·A company with strong science but weak data-room readiness
·A promising Brazilian technology needing North American positioning

Founder Guides

Practical founder-facing content on how to prepare biological products for fundraising, regulatory submission, and field validation. Written so the next conversation with an investor or a regulator goes better than the previous one.

Planned pieces include

·What investors will ask about your biological product
·Preparing a biologicals data room
·Translating field-trial evidence for investors
·How to avoid overclaiming biological performance

Notifications

Be notified when articles publish.

Send your name, email, and a short note saying which categories interest you most. We will let you know when relevant pieces publish.

Confidential by default. Not sold. Not published. Not shared without permission.

The framework behind the writing: See QBIView → · Looking for the company's track record? Read Patrícia's track record →